Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 1;12(7):1343–1355. doi: 10.1158/1535-7163.MCT-13-0100

Figure 3.

Figure 3

Topotecan lactone pharmacokinetic variables (A) Area under the plasma concentration-time curve (AUCinf) (B) Systemic clearance (CL) and (C) Volume of distribution (Vd) in male C57BL/6 WT, Abcc2−/−, Abcc4−/−, Abcb1−/−, Abcg2−/−, Abcc2;Abcg2, Abcc4;Abcg2−/− and Abcc2;Abcb1−/− mice, after IV administration of 1 mg/kg and 4 mg/kg topotecan. The pharmacokinetic parameters were estimated by noncompartmental analysis using WinNonlin Professional Version 5.2. The statistical differences were determined using the One-Way ANOVA with Tukey's multiple comparison (GraphPad Prism version 5.04) tests to compare inter-strain differences. Data are expressed as mean values of the AUC, CL or Vd ± SD (n = 5–9; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with wild-type; #, P < 0.05; ##, P < 0.01; ###, P < 0.001 compared with Abcc2−/−).